Berlin, 1 October 2026
In its final arbitration ruling, the arbitration board (Schiedsstelle) considers a 15% discount on the reimbursement amount to be appropriate, as negotiated in an analogous procedure between the manufacturer and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) for the active substance fedratinib.
In its first interim arbitration ruling, the arbitration board had considered itself competent in cases where, after a routine practice data collection (anwendungsbegleitende Datenerhebung, AbD) has not been started, the GKV-Spitzenverband calls on the pharmaceutical manufacturer to conclude a supplementary agreement on the reimbursement amount and the parties are unable to reach an agreement.